Source:http://linkedlifedata.com/resource/pubmed/id/21127708
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:dateCreated |
2010-12-3
|
pubmed:abstractText |
The aim of this study was to investigate whether the VKORC1*3 (rs7294/9041 G?>?A), VKORC1*4 (rs17708472/6009 C?>?T), and CYP4F2 (rs2108622/1347 C?>?T) polymorphisms were associated with elevated warfarin maintenance dose requirements in patients with myocardial infarction (n = 105) from the Warfarin Aspirin Reinfarction Study (WARIS-II). We found significant associations between elevated warfarin dose requirements and VKORC1*3 and VKORC1*4 polymorphisms (P = .001 and P = .004, resp.), whereas CYP4F2 (1347 C?>?T) showed a weak association on higher warfarin dose requirements (P = .09). However, analysing these variant alleles in a regression analysis together with our previously reported data on VKORC1*2, CYP2C9*2 and CYP2C9*3 polymorphisms, gave no significant associations for neither VKORC1*3, VKORC1*4 nor CYP4F2 (1347 C?>?T). In conclusion, in patients with myocardial infarction, the individual contribution to warfarin dose requirements from VKORC1*3, VKORC1*4, and CYP4F2 (1347 C?>?T) polymorphisms was negligible. Our results indicate that pharmacogenetic testing for VKORC1*2, CYP2C9*2 and CYP2C9*3 is more informative regarding warfarin dose requirements than testing for VKORC1*3, VKORC1*4, and CYP4F2 (1347 C?>?T) polymorphisms.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/CYP4F2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Cytochrome P-450 Enzyme System,
http://linkedlifedata.com/resource/pubmed/chemical/Mixed Function Oxygenases,
http://linkedlifedata.com/resource/pubmed/chemical/Warfarin,
http://linkedlifedata.com/resource/pubmed/chemical/vitamin K epoxidase
|
pubmed:status |
MEDLINE
|
pubmed:issn |
1110-7251
|
pubmed:author |
pubmed-author:BergJens PetterJP,
pubmed-author:BrørsOddO,
pubmed-author:FosenJan ToralfJT,
pubmed-author:GrimholtRuna MRM,
pubmed-author:HaugKari Bente FossKB,
pubmed-author:JohansenPer WPW,
pubmed-author:KringenMarianne KMK,
pubmed-author:NarumSigridS,
pubmed-author:OpdalMimi SMS,
pubmed-author:PiehlerArmin PAP,
pubmed-author:SeljeflotIngebjørgI,
pubmed-author:StormoCamillaC
|
pubmed:issnType |
Electronic
|
pubmed:volume |
2011
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
739751
|
pubmed:meshHeading |
pubmed-meshheading:21127708-Cytochrome P-450 Enzyme System,
pubmed-meshheading:21127708-Dose-Response Relationship, Drug,
pubmed-meshheading:21127708-Humans,
pubmed-meshheading:21127708-Mixed Function Oxygenases,
pubmed-meshheading:21127708-Myocardial Infarction,
pubmed-meshheading:21127708-Polymorphism, Single Nucleotide,
pubmed-meshheading:21127708-Regression Analysis,
pubmed-meshheading:21127708-Statistics, Nonparametric,
pubmed-meshheading:21127708-Warfarin
|
pubmed:year |
2011
|
pubmed:articleTitle |
Genetic variation of VKORC1 and CYP4F2 genes related to warfarin maintenance dose in patients with myocardial infarction.
|
pubmed:affiliation |
Department of Pharmacology, Oslo University Hospital, Ullevål, Oslo, Norway. m.k.kringen@medisin.uio.no
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|